News
RARE
42.49
-2.37%
-1.03
Noteworthy Friday Option Activity: RARE, TEAM, MDT
NASDAQ · 1d ago
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views
Benzinga · 2d ago
Ultragenyx price target raised to $86 from $73 at TD Cowen
TipRanks · 2d ago
Wedbush Sticks to Their Hold Rating for Ultragenyx Pharmaceutical (RARE)
TipRanks · 2d ago
Morgan Stanley Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
TipRanks · 2d ago
Ultragenyx Pharmaceutical: Promising Growth Prospects with Strong Financial Outlook and Key Pipeline Developments
TipRanks · 2d ago
Ultragenyx Pharma Price Target Maintained With a $95.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $95 Price Target
Benzinga · 2d ago
Piper Sandler Remains a Buy on Ultragenyx Pharmaceutical (RARE)
TipRanks · 2d ago
Analysts Are Bullish on Top Healthcare Stocks: CVS Health (CVS), Ultragenyx Pharmaceutical (RARE)
TipRanks · 2d ago
Ultragenyx Pharmaceutical (RARE) Gets a Buy from RBC Capital
TipRanks · 2d ago
Promising Developments in Ultragenyx Pharmaceuticals Drive Ed Arce’s Buy Rating
TipRanks · 2d ago
ULTRAGENYX PHARMACEUTICAL INC <RARE.O>: TD COWEN RAISES TARGET PRICE TO $86 FROM $73
Reuters · 2d ago
Ultragenyx Pharmaceutical Reports Strong 2024 Growth
TipRanks · 2d ago
Ultragenyx projects $640M-$670M in 2025 revenue growth driven by product launches
Seeking Alpha · 2d ago
Ultragenyx Pharmaceutical’s Strong Sales and Promising Pipeline Support Buy Rating
TipRanks · 2d ago
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
NASDAQ · 2d ago
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 2d ago
Ultragenyx Pharmaceutical GAAP EPS of -$1.39 misses by $0.10, revenue of $164.88M beats by $6.17M
Seeking Alpha · 2d ago
Ultragenyx sees FY25 revenue $640M-$670M, consensus $651.93M
TipRanks · 2d ago
More
Webull provides a variety of real-time RARE stock news. You can receive the latest news about Ultragenyx Pharm through multiple platforms. This information may help you make smarter investment decisions.
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.